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Material and Methods: Thirty-four patients were included in 
a period from 1994 until 2013. Patients’ charts were 
reviewed to obtain patients’, treatment and tumor 
characteristics. DVH parameters were analyzed after 
reconstruction of the original brachytherapy plan plus 
delineation of intermediate risk CTV (CTVIR) and organs at 
risk. The target volume at time of BT was the GTVres and 
was defined by the treating doctor based on clinical 
examination and CT scan. The CTVIR was defined by the 
tumor extension at time of diagnosis. Survival rates were 
calculated using the Kaplan-Meier method. Morbidity was 
scored by CTCAE v3.0. 
 
Results: Nine (26%) patients had FIGO stages I; 13 (38%) II; 5 
(15%) III and 7 (21%) IVA. Median age at diagnosis was 68 
years (33-91). Median follow-up was 37 months (3-224). 
Thirty-two patients received whole pelvic external beam 
radiotherapy (EBRT) to a median dose of 46 Gy (45-50.4 Gy), 
followed by BT in 31 patients; two patients received BT 
alone. The median D90 and D98 of the GTVres were 68 Gy 
and 67 Gy respectively, with a median V100 of 88%. The 
median D90 and D98 of the CTVIR were 65 Gy and 61 Gy 
respectively, with a median V100 of 62%. Complete remission 
at 3 months was achieved in all but one patient. Overall 
survival (OS) rates at 2- and 5-years were respectively 76% 
and 41%. Eight (24%) patients had any grade ≥3 toxicity. Local 
recurrences were seen in seven (21%) patients of whom three 
had an isolated local recurrence. Patients’ and treatment 
characteristics of this group are shown in Table 1. Although 
the coverage of the GTVres seemed adequate, in retrospect 
it was often disputable if the tumor at BT was fully covered 
due to poor visibility of the tumor on CT scan. 
 
 
 
 
Conclusion: The combination of EBRT and BT with or without 
concomitant chemotherapy provides reasonable outcomes in 
terms of tumor control and toxicity. However, there is still 
room for improvement. This study was too small to illustrate 
clear dose-effect relationships. In general, the prescribed 
dose on target at time of BT (GTVres) seemed low. In 
addition, coverage of the CTVIR was poor, which can however 
be explained by the fact that until recently our target at BT 
was exclusively based on GTVres. Finally, the use of MRI at 
time of BT seems necessary to better define the target. 
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Purpose or Objective: To evaluate the treatment results, 
and complication rates in patients with locally advanced 
cervical cancer after external beam radiotherapy (EBRT) and 
high-dose rate (HDR) brachytherapy with dose escalation. 
 
Material and Methods: All patients with locally advanced 
cervical cancer (FIGO: IB 7 patients, II 10 patients, III 7 
patients, IV 4 patients) treated with radical radiotherapy in 
our center from 2007 to October 2015 were reviewed. 
Twenty eight patients were treated with EBRT using 
intensity-modulated radiation therapy (IMRT) technique 
following by HDR brachytherapy +/- chemotherapy. 
Planification included CT (50%) or PET-CT (50%) for GTV 
delineation. The most common prescription was 50.4 Gy 
(1.8Gy per fraction) for pelvic lymph nodes +/- paraaortic 
lymph node with concomitant boost up to 60, 48 Gy (2,16Gy 
per fraction) for macroscopic nodal disease and parametrium 
affectation. HDR brachytherapy was applied using tandem (25 
Gy in 5 fractions) in most patients. Toxicity was assessed 
according to RTOG-EORTC criteria. All statistical analysis was 
performed using SPSS vs 22.0. 
 
Results: There was no grade 3 acute toxicity associated with 
EBRT. Only one case of grade 4 acute toxicity was observed 
after HDR gynecological brachytherapy. The median age was 
51 years (range 39 – 81). The median of follow up was 30 
months (range 4 – 85). The actuarial progression-free survival 
was 77% at 36 months. Median time to local progression has 
not been reached. The median overall survival was 30 (range 
4-85) month. 
 
Conclusion: Radical radiotherapy +/- chemotherapy is still a 
standard treatment in locally advanced uterine cervical 
cancer with good local control and global survival. Dose 
escalation is possible using PET-CT and IMRT which allow 
better conformation and better tolerance.  
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Purpose or Objective: To determine clinical efficacy and 
toxicity of weekly nimotuzumab plus cisplatin concurrent 
with intensity-modulated radiotherapy in Chinese women 
with locally advanced cervical cancer. 
 
Material and Methods: Between December 2013 and July 
2015, a total of 27 patients with primary carcinoma of the 
cervix, FIGO stage IB1 to IVa, squamous cell carcinomas 
confirmed by histology were enrolled into this study. 26 
patients received intensity modulated radiotherapy and 5 ~ 6 
fractions HDR brachytherapy, 1 patient received intensity 
modulated radiotherapy followed by surgery because she had 
rectum carcinoma at the same time. Chemotherapy scheme 
was 200 mg nimotuzumab and 40 mg/m2 cisplatin weekly for 
six cycles. 2 patients (ages: 78 ~ 79) received only 200 mg 
nimotuzumab weekly for six cycles. The patients were 
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monitored for acute toxicity using the Common Toxicity 
Criteria, version 3.0 and late toxicity using the RTOG/EORTC. 
 
Results: 3° (9/27) hematologic toxicity, principally 
neutropenia (9/27) and thrombocytopenia (2/27), occurs late 
cycles. No grade 4 toxicity occurred. 2 patients (ages: 78~79) 
finished 200 mg nimotuzumab weekly for six cycles with 1° 
hematologic. Others finished 5 ~ 6 cycles chemotherapy. All 
of patients finished radiotherapy in 7 ~8 weeks. The median 
follow-up was 9.5 months (3 ~ 22). At 4 months, 24 patients 
had attained complete response (23 CR, 1 pCR), 3 patients 
had achieved partial response (PR). 2 of 3 patients who had 
PR appeared local recurrent at 8 months and 9 months 
respectively. Local control rates were 92.6 %（25/27）. All of 
patients are still survive. 1 patient had haemorrhagic 
radiation proctitis at 7 months. 
 
Conclusion: Combination nimotuzumab 200 mg and DDP 40 
mg/m2 weekly for six cycles concurrently with intensity-
modulated radiotherapy can be safely administered in 
Chinese women. Primary result showed a good clinical 
outcome. We need continue follow-up. Further development 
to determine if the combination will help yield a survival 
benefit. 
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Purpose or Objective: stereotactic body radiotherapy (SBRT) 
has emerged as an effective treatment for localized prostate 
cancer. However, prostate-specific antigen (PSA) kinetics 
after SBRT has not been well characterized. The objective of 
the current study is to analyze the rate of PSA decline and 
PSA nadir following hypofractonated SBRT in low- and 
intermediate-risk prostate cancer. 
 
Material and Methods: From 2008 to 2014, thirty-six patients 
newly diagnosed, low- and intermediate-risk (NCCN 
definition) prostate cancer were treated with SBRT using 
Cyberknife. Total dose of 36.25 Gy in 5 fractions of 7.25 Gy 
were administered. No one received androgen deprivation 
therapy (ADT). PSA nadir and rate of change in PSA (slope) 
were calculated and compared. 
 
Results: With a median follow-up of 52 months (range, 13-
71), the median rates of decline of PSA were -0.359, -0.199 
and -0.127 ng/mL/month, respectively, for durations of 1, 2 
and 3 years after radiotherapy, respectively. The decline of 
PSA was maximal in the first year and continuously decreased 
for durations of 2 and 3 year. The median PSA nadir was 0.27 
ng/mL after a median 33 months. 5-year biochemical failure 
(BCF)-free survival was 100% for low- and intermediate-risk 
patients. 
 
Conclusion: In this report of low- and intermediate-risk 
prostate cancer, continuous decrease of PSA level for 
duration 1, 2 and 3 year following SBRT using Cyberknife 
resulted in lower PSA nadir. Also, SBRT leaded to long-term 
favorable BCF-free survival in low- and intermediate-risk 
prostate cancer. 
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Purpose or Objective: Hypofractionated stereotactic body 
radiotherapy (SBRT) has emerged as an effective treatment 
for localized prostate cancer. However, prostate specific 
antigen (PSA) kinetics after SBRT has not been well 
characterized. The purpose of this study was to compare the 
PSA kinetics between SBRT using Cyberknife and 
conventionally fractionated external beam radiotherapy (CF-
EBRT) in low- and intermediate-risk prostate cancer. 
 
Material and Methods: A total of sixty-nine patients with 
low-and intermediate-risk prostate cancer were enrolled. 34 
patients were treated with SBRT (36.25Gy in 5 fractions) 
using Cyberknife and 35 patients treated with CF-EBRT (45 Gy 
whole pelvis EBRT and boost of 25.2-30.6 Gy in 1.8 Gy 
fractions). PSA nadir and rate of PSA decline in PSA (slope) 
were calculated and compared. 
 
Results: With a median follow-up of 53.6 months (range, 14-
74), the median PSA nadir and median slope for SBRT were 
0.23 ng/mL and -0.430, -0.199, -0.127 and -0.094 
ng/mL/month, respectively, for durations of 1, 2, 3 and 4 
years following radiotherapy. Similarly, for CF-EBRT, the 
median PSA nadir and median slopes were 0.37 ng/mL and -
0.529, -0.138, -0.109 and -0.056 ng/mL/month, respectively. 
The slope of CF-EBRT was significantly different with a 
greater median rate of change for 1 year post radiotherapy 
than that of SBRT (p=0.018). Contrastively, the slopes of 
SBRT for duration for 2, 3 and 4 year tended to be 
continuously greater than that of CF-EBRT (p=0.028, p=0.058 
and p=0.128, respectively). The significantly lower PSA nadir 
was observed in SBRT (median nadir 0.23 ng/mL) compared 
with CF-EBRT (median nadir 0.37ng/mL) (p=0.011). 5-year 
biochemical failure (BCF) free survival were 100% for SBRT 
and 80.8% for CF-EBRT (p=0.031). 
 
Conclusion: Patients treated with SBRT using Cyberknife 
experienced a lower PSA nadir and tended to be continuously 
greater rate of decline of PSA for duration 2, 3 and 4 years 
than CF-EBRT. The improved PSA kinetics of SBRT over CF-
EBRT leaded to favorable BCF-free survival. Further studies 
with more patients and longer follow-up duration are 
required. 
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Purpose or Objective: to analyze predictors of genitourinary 
(GU) toxicity in a cohort of prostate cancer (PC) patients 
treated with moderate hypofractionation and simultaneous 
integrated boost (SIB) using volumetric modulated arc 
therapy (VMAT) technique. 
 
Material and Methods: Clinical and dosimetric data were 
prospectively collected and retrospectively analyzed. 
Patients were stratified into low (43%), intermediate (30%) 
and high-risk (27%) groups. Target volumes (expanded to 
define the planning volumes (PTV)) were clinical target 
volume (CTV) 1: prostate; CTV2: CTV1 + seminal vesicles; 
CTV3: CTV2 + pelvic nodes. Low-risk patients received 73.5 
Gy to PTV1; intermediate-risk 73.5 Gy to PTV1 and 60 Gy to 
PTV2; high-risk 73.5 Gy to PTV1, 60 Gy to PTV2, and 54 Gy to 
PTV3. All treatments were in 30 fractions. Androgen 
deprivation therapy (ADT) was prescribed upfront in 
intermediate and high risk patients. Rectal and GU toxicities 
were scored according to Common Terminology Criteria for 
Adverse Events v4.0 scoring system. 
 
Results: From January 2012, 60 patients with localized PC 
were recruited in an internal protocol of moderate 
hypofractionation SIB schedule using VMAT technique with 
definitive intent. The median follow-up was 24 months (range 
10 - 36 months). GU acute toxicity was recorded as follow: 
G0 = 16/60 (27%), G1 = 18/60 (30%); G2= 26/60 (43%); no 
case of toxicity ≥ G3 was registered. GU late toxicity was 
recorded as follow: G0 = 20/60 (34%); G1 = 29/60 (48%); G2 = 
11/56 (19%); no case of toxicity ≥ G3 was registered. The risk 
